Eaton Vance Management Avadel Pharmaceuticals PLC Transaction History

Eaton Vance Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $29,696 - $45,089	-5,439 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.34 - $11.18 $46,931 - $71,484	-6,394 Reduced 54.04%	5,439 $44,000
Q3 2021 Nov 15, 2021	SELL	$6.49 - $9.91 $131,759 - $201,192	-20,302 Reduced 63.18%	11,833 $116,000
Q3 2019 Nov 14, 2019	SELL	$1.92 - $4.47 $4,924 - $11,465	-2,565 Reduced 7.39%	32,135 $134,000
Q3 2017 Nov 13, 2017	BUY	$8.35 - $10.5 $289,745 - $364,350	34,700	34,700 $364,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $626M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.